Abstract Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype that lacks effective targeted therapies. The epithelial-to-mesenchymal transition (EMT) is a key contributor in the metastatic process. We previously showed the pan-deacetylase inhibitor LBH589 induces CDH1 expression in TNBC cells, suggesting regulation of EMT. The purpose of this study was to examine the effects of LBH589 on the metastatic qualities of TNBC cells and the role of EMT in this process. A panel of breast cancer cell lines (MCF-7, MDA-MB-231, and BT-549), drugged with LBH589, was examined for changes in cell morphology, migration, and invasion in vitro. The effect on in vivo metastasis was examined using immunofluorescent staining of lung sections. EMT gene expression profiling was used to determine LBH589-induced changes in TNBC cells. ZEB overexpression studies were conducted to validate requirement of ZEB in LBH589-mediated proliferation and tumorigenesis. Our results indicate a reversal of EMT by LBH589 as demonstrated by altered morphology and altered gene expression in TNBC. LBH589 was shown to be a more potent inhibitor of EMT than other HDAC inhibitors, SAHA and TMP269. Additionally, we found that LBH589 inhibits metastasis of MDA-MB-231 cells in vivo. These effects of LBH589 were mediated in part by inhibition of ZEB, as overexpression of ZEB1 or ZEB2 mitigated the effects of LBH589 on MDA-MB-231 EMT-associated gene expression, migration, invasion, CDH1 expression, and tumorigenesis. These data indicate therapeutic potential of LBH589 in targeting EMT and metastasis of TNBC.
Introduction
Triple-negative breast cancer (TNBC) is a heterogeneous subset of neoplasms defined by the absence of estrogen receptor and progesterone receptor, and non-amplification of Her2/neu [1] [2] [3] , representing approximately 15 % of diagnosed breast cancer cases [3, 4] . Studies have shown that tumors of this aggressive subtype are of higher histological grade and affect a disproportionate number of young women [1-3, 5, 6] . Although TNBC primary tumor display a better initial response to chemotherapy compared to estrogen receptor-positive tumors, TNBC patients have a worse prognosis regardless of tumor stage at diagnosis [3] . The poor prognoses of TNBC appear to be linked to the presence of residual or disseminated disease, as many TNBC patients present with metastatic disease much earlier than their estrogen receptor-positive counterparts, typically within the first 3 years after diagnosis [3] . The high rate of metastasis coupled with the fact that these disseminated cells frequently display multidrug resistance [7] make treatment of metastatic disease difficult [1-3, 5, 6] . The lack of classical therapeutic targets (ER, Her2/neu) and the increased risk of metastasis in the TNBC subtype make identifying and developing novel therapeutics critical for the treatment of these patients.
Histone deacetylase inhibitors (HDACis) have emerged as a promising new class of multifunctional anticancer agents [8, 9] . That promise lies in the ability of HDACis to affect multiple epigenetic changes in aberrant cells. Panobinostat (LBH589) is a potent pan-deacetylase inhibitor that can block multiple cancer-related pathways and reverse epigenetic events implicated in cancer progression [10] . In addition to the anti-cancer effects of LBH589 observed in hematologic, lung, thyroid, and prostate malignancies, our previous results show significant effects in the triple-negative subtype of breast cancer [11] . Our studies revealed decreased cell proliferation and viability, increased apoptosis, as well as inhibition of primary tumor volumes of TNBC xenografts. Significant increases in the epithelial cell marker CDH1 following treatment with LBH589 both in vitro and in vivo led us to question the effects of LBH589 on the epithelial-to-mesenchymal transition (EMT) of TNBC and, thus, the effects on cell motility and metastasis.
The EMT has been recognized as a major player in cancer cell invasion and metastasis [12] . EMT is characterized by the loss of epithelial cell markers, namely epithelial-cadherin (CDH1), enhanced expression of mesenchymal cell markers, including neuronal-cadherin (CDH2) and vimentin (VIM), and increased expression of CDH1 transcriptional repressors such as zinc finger E-boxbinding homeobox 1 (ZEB1) and 2 (ZEB2) [13] [14] [15] [16] . The expression of EMT markers, including CDH1, CDH2, VIM, ZEB1, and ZEB2, has been associated with poor prognosis of breast cancer patients [17, 18] . As such, regulators of EMT have become attractive targets for the development of anti-metastasis therapies. Here, we demonstrate the ability of LBH589 to inhibit the migration, invasion, and metastasis of TNBC cell lines via suppression of EMT. Furthermore, we reveal a role for ZEB expression in the LBH589-mediated anti-EMT effects in TNBC cells. Together our data support the development of LBH589 as a novel therapeutic to target the aggressive and metastatic nature of TNBC.
Materials and methods

Cell lines and reagents
Human TNBC (MDA-MB-231, BT-549) cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). MDA-MB-231 and BT-549 cells are characterized as triple-negative/basal-B mammary carcinoma [19] . Liquid nitrogen stocks were made upon receipt and maintained until the start of each study. MCF-7 cells, characterized as ER-positive/PgR-positive luminal mammary carcinoma, were obtained from frozen stocks routinely used and previously published [20] . Cells were used for no more than 6 months after being thawed with periodic recording of morphology and doubling times to ensure maintenance of phenotype. Cells were maintained at 37°, 5 % CO 2 in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10 % fetal bovine serum (Hyclone, Salt Lake City, UT, USA) and 1 % penicillin/streptomycin (Invitrogen). Panobinostat was generously provided by Novartis Pharmaceutical Inc. (East Hanover, NJ, USA). SAHA was purchased from Cayman Chemicals (Ann Arbor, MI, USA) and TMP269 from Xcess Biosciences Inc. (San Diego, CA, USA). Panobinostat (LBH589), SAHA, and TMP269 were dissolved in dimethyl sulfoxide (DMSO) (Invitrogen) as a 10-mM stock solution and stored at -20°C. Drugs were diluted in culture media and used at concentrations indicated.
Crystal violet assay
Cells were plated at 7.5 9 10 3 cells per well in a 96-well plate format in 100 ll 5 % charcoal/dextran treated fetal bovine serum (Atlanta Biologicals, Atlanta, GA, USA) phenol red-free DMEM (5 % CS-DMEM) and allowed to attach overnight at 37°C, 5 % CO 2 . Cells were treated the next day at concentrations indicated. After 3 days of treatment, plates were harvested by the addition of 10 ll gluteraldehyde per well incubated at room temperature for 30 min. Cells were washed and allowed to dry. Cells were stained with 50 ll of 0.1 % crystal violet (in 20 % methanol) for 30 min, washed and allowed to dry. Cells were imaged on a Nikon TE2000 inverted microscope with IPLab software (BD Biosciences, Rockville, MD, USA). Original images were taken at 2009 magnification. Cells were lysed with 100 ll 33 % acetic acid and absorbance read at 630 nm.
Transwell migration and invasion assays
Migration assays were performed following the manufacturer's instructions (BD Biosciences) and as previously published [21] . Cells were treated at time of plating. After 6 or 24 h (as noted in the legend), migrated cells were fixed to the membranes and stained with crystal violet (0.1 % in 20 % methanol), and migrated cells visualized and quantified by microscopy. Invasion assays were conducted in the same manner as the migration assays using Matrigel Immunohistochemical staining and quantitation Staining was conducted as previously published [11, 22] . RFP staining rabbit anti-RFP (Abcam, Cambridge, UK) 1:30 dilution, Alexa Fluor Ò 488 goat anti-rabbit secondary (Invitrogen); CDH1 staining: rabbit E-cadherin antibody (24E10; Cell Signaling Technology, Boston, MA, USA) 1:400 dilution. Internal negative controls were exposed to rabbit IgG or 10 % goat serum rather than primary antibody. Images were captured on a Nikon TE2000 inverted microscope with IPLab software (BD Biosciences, Rockville, MD, USA), original magnification at 2009 (RPF) or 4009 (CDH1).
Metastases were calculated as a ratio of the number of RFP-positive cells versus the total amount of cells (determined by DAPI nuclear stain) per field of view. Points represent the ratio of RPF-positive cells versus DAPI for each section examined with mean for each group represented as horizontal black bar. SEM for each group indicated in red.
RNA isolation
Cells were plated in 10 % DMEM at 70 % confluency and treated with 100 nM LBH589 or vehicle for 24 h. Cells were harvested by trypsinization, and total RNA was isolated using the RNeasy kit, according to the manufacturer's instructions (Qiagen, Valencia, CA, USA). The quantity and quality of the RNA were determined by absorbance at 260 and 280 nm using the NanoDrop ND-1000 (NanoDrop, Wilmington, DE, USA).
Human EMT quantitative reverse transcription realtime PCR array Human EMT RT 2 Profiler TM PCR Arrays (PAHS-090 and 090Z) were obtained from SABiosciences (Frederick, MD, USA) and assayed according to manufacturer's protocol. Biological triplicates were run for each sample.
Quantitative reverse transcription real-time PCR Total RNA was reverse-transcribed using the BioRad First Strand cDNA synthesis kit, following the manufacturer's protocol (BioRad) and then assayed via quantitative realtime PCR (qPCR) to assess gene expression changes as previously published [21] . Primers are available in supplemental materials. Data represented as normalized DDC t (fold expression) compared to control samples of biological triplicate samples ± SEM.
Western blot analysis
Western blot analyses were conducted as previously published [21] . Primary antibodies were used at a concentration of 1:100. ZEB1 (H-102) was purchased from Santa Cruz Biotechnology (Dallas, TX) and ZEB2/SIP1 (6E5) from Millipore (Billerica, MA). Secondary antibodies (IRDye) were used at 1:10,000 and purchased from Licor Bioscience (Lincoln, NE).
MTT cell proliferation assay
Proliferation of MDA-MB-231-ZEB1, ZEB2, and vector cells was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Cell Proliferation Assay, according to the manufacturer's protocol (Invitrogen) as previously published [11] . 5 9 10 3 cells/well were plated in 96-well format in 10 % DMEM. Cells were treated with LBH589 (100 nM) or vehicle for 24 h. Data represented as mean percent vehicle-treated MDA-MB-231-vector cell proliferation ± SEM of biological triplicate experiments with internal duplicates.
CDH1 ELISA
MDA-MB-231-vector, -ZEB1, and ZEB2 were treated with LBH589 or vehicle (DMSO) for 24 h, and used for ELISA to determine CDH1 protein changes. CDH1 ELISA was purchased from R&D Systems (Minneapolis, MN) conducted per manufacturer's instructions and as previously published [11] .
Animal xenograft studies
Xenograft tumor studies were conducted as previously described [20] . At necropsy, animals were euthanized by cervical dislocation following CO 2 exposure. Tumors, livers, lungs, and brains were removed and snap frozen or fixed in 10 % formalin for future analysis. All procedures involving animals were conducted in compliance with State and Federal laws, the U.S. Department of Health and Human Services, and guidelines established by Tulane University Animal Care and Use Committee. The facilities and laboratory animals programs of Tulane University are accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.
Quantification of brain metastases
At necropsy mouse brains were removed, and half of each brain was placed in 1-ml saline containing 0. ZEB1 and ZEB2 stable cell generation MDA-MB-231 cells were plated at approximately 50 % confluency in 10 cm 2 culture dishes in 10 % DMEM and allowed to adhere overnight in a 37°C incubator. The following day cells were transfected with 5 lg of CMVeGFP vector, CMV-eGFP-ZEB1, or CMV-eGFP-ZEB2 (GeneCopoeia, Rockville, MD, USA) plasmids using Attractene (Qiagen, Germantown, MD, USA) per manufacturer's instructions. After 24 h, the transfection media was replaced with fresh culture media, and cells treated with neomycin to select for transfected cells. Cells were also monitored for GFP expression. Upon stable selection, pooled populations were confirmed by qPCR (Supplemental Fig. 2a, b ) and western blot (Supplemental Fig. 2c ).
Statistical analyses
Statistical analyses were carried out with GraphPad Prism software (Graph-Pad Software, Inc., San Diego, CA, USA).
Studies involving more than two groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey's post hoc multiple comparison tests. All others were subjected to unpaired Student's t test, with p \ 0.05 considered statistically significant.
Results
LBH589 alters TNBC morphology and inhibits EMTassociated gene expression
Our previously published findings suggest a partial reversal of EMT in TNBC following LBH589 treatment as indicated by increased CDH1 expression and cell morphology changes [11] . We further examined this effect in a longterm morphological crystal violet (CV) assay to compare the effects of LBH589 to two other known HDACi, SAHA (class I and II inhibitor) and TMP269 (class IIa inhibitor). Figure 1a depicts representative images of MDA-MB-231, BT-549, and MCF-7 cells treated with LBH589, SAHA, TMP269 (10 nM), or vehicle control (DMSO) for 3 days. Altered morphology suggestive of the reversal of EMT or mesenchymal-to-epithelial transition (MET) is evident in the majority of cells treated with LBH589; similar effects were not observed in the other treatment groups until much higher doses (SAHA 100 nM, TMP269 1-10 lM; data not shown). Quantitation of the CV assay dose response (10 nM-10 lM) in MDA-MB-231 cells demonstrated a similar effect on cell proliferation by LBH589 as previously observed [11] , while SAHA and TMP269 were much less effective (Fig. 1b) . Similar results were observed in BT-549 and MCF-7 cells (Supplemental Fig. 1a, b) . Gene expression changes of known EMT-regulated genes were also examined following treatment with HDACi. LBH589 shows a significant increase in CDH1 and a decrease in VIM, ZEB1, and ZEB2, while SAHA and TMP269 show no significant effects in EMT-related gene expression in MDA-MB-231 (100 nM for 24 h) (Fig. 1c) . A similar trend in EMT-regulated gene expression was observed in the BT-549 cells when treated with LBH589, while no effect or a reversed effect was observed with the other HDACi (Supplemental Fig. 1c) . Additionally, MCF-7 cells showed no effect on EMT gene expression when treated with LBH589 ( Supplemental Fig. 1d ). The effect of LBH589 on breast cancer cell morphology was further examined using the electrical cell-substrate impedance sensing (ECIS) system, which monitors the flow of alternating current under and between cell culture monolayers to determine changes in surface coverage and cell-cell junctions in real time. ECIS studies revealed a nearly immediate increase in resistance (*4,900 to *6,800 X) and decrease in capacitance (*3.5 to *2.2 nF) of MDAb Fig. 1 LBH589 alters morphology, EMT-associated 3 in a 96-well plate were treated with LBH589, SAHA, TMP269 (10 nM-10 lM) or vehicle (DMSO). After 3 days, cells were stained with CV and lysed. Points indicate mean absorbance at 630 nM ± SEM. Similar results were observed in BT-549 but not MCF-7 cells (Supplemental Fig. 1a, b) . c EMTrelated gene expression analysis (qPCR) of MDA-MB-231 cells treated with LBH589, SAHA, TMP269 (100 nM) or vehicle (DMSO) or 24 h. Similar trends were seen in BT-549 cells but not MCF-7 cells (Supplemental Fig. 1c, d) .
Ò (e invasion). Cells were treated with LBH589 (100 nM) or vehicle control at time of plating. Lower wells contained DMEM supplemented with 10 % FBS. After 24 h, migrated or invaded cells were fixed and stained for visualization. Bars represent relative migration or invasion compared to MCF-7 cell vehicle treatment set to 1 ± SEM. Experiments were conducted in triplicate. *p \ 0.05; **p \ 0.01; ***p \ 0.001 MB-231 cell monolayers following LBH589 treatment (Supplemental Fig. 2a, b) . The resistance and capacitance of MCF-7 cells treated with LBH589 remained unchanged (Supplemental Fig. 2c, d) . These data indicate a rapid increase in cell-cell tight junctions (resistance) and surface coverage (capacitance) of MDA-MB-231 cells treated with LBH589, consistent with the morphology changes observed and a more epithelial phenotype.
LBH589 reduces the migratory and invasive potential of TNBC cells in vitro
To determine if these changes translated to altered biological responses, the effects of LBH589 on cell migration and invasion were tested. Treatment with LBH589 for 24 h reduced both the migratory (Fig. 1d) and invasive (Fig. 1e) abilities of all cells lines tested; however, the most 
LBH589 reduces metastasis of MDA-MB-231 cells to the lung and brain in vivo
The EMT phenotype, cell migration, and invasion have all been linked to enhanced metastatic potential of cancer cells [12] . Our observation of increased expression of the epithelial cell marker CDH1 as well as inhibition of the migratory and invasive responses of TNBC cell led us to examine the tissues of animals from our previously published in vivo study for distant metastases [11] . SCID/beige mice injected in the mammary fat pad with MDA-MB-231-tRFP cells were treated with i.p. injections of LBH589 (10 mg/kg) or vehicle control for 28 days. At necropsy, lungs were harvested and fixed in 10 % formalin for 2 days and then processed and embedded in paraffin. Sections were cut and stained for H&E (Fig. 2a, first column) , or anti-RFP (Fig. 2a , second column) with DAPI nuclear stain (Fig. 2a, third column) , and the number of RFP-positive cells quantified. Higher magnification inserts are shown of the red-bordered area and white arrows indicate areas of metastatic cells within the lung. As shown in Fig. 2b , LBH589 treatment significantly reduced the number of metastatic cells present in the lung (p \ 0.05). Additionally, the LBH589 treated animals also demonstrated a significant reduction in metastatic cells present in the brain compared to vehicle-treated cells (Fig. 2c, p \ 0.001 ).
LBH589 treatment alters the expression of EMTassociated gene reflective of inhibition of EMT
These results along with our previously observed LBH589-induction of CDH1 expression in TNBC cells [11] led us to further examine the effects of LBH589 treatment on EMT. Using qPCR superarrays, 84 EMT-associated genes were examined following treatment with LBH589 for 24 h in two triple-negative cell lines (MDA-MB-231, BT-549) and an estrogen receptor-positive, luminal cell line (MCF-7). Table 1 summarizes the significant changes in gene expression common to the triple-negative cell lines (full array data available in Supplemental Tables 1, 2, 3) . Genes differentially expressed between subtypes (TNBC vs. luminal) are indicated in bold print. LBH589 treatment significantly induced expression of 24 genes while significantly repressing 4 genes in the TNBC cell lines. Of those genes upregulated by LBH589, eight are known to be downregulated during EMT or metastasis (CDH1, ERBB3, F11R, FGFBP1, KRT19, RGS2, TFPI2, TSPAN13) [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Additionally, all of the genes significantly downregulated by LBH589 in TNBC are commonly upregulated during EMT (FZD7, WNT5B, ZEB1, ZEB2) [17, [37] [38] [39] [40] . These data suggest that LBH589 induces an anti-EMT gene expression profile in TNBC cell lines. Interestingly, LBH589 treatment differentially affected expression of EMT genes in luminal A (MCF-7) cells compared to the triple-negative subtype, again suggesting subtype-specific effects of LBH589 for the more aggressive TNBC subtype noted in our previous publication [11] .
Forced expression of ZEB1 or ZEB2 abrogates the effects of LBH589 on markers of EMT Again, we found CDH1 expression levels to be significantly elevated following LBH589 treatment in the two triple-negative lines, while no change was observed in the ER-positive line. Additionally, expression of ZEB1 and ZEB2, direct regulators of CDH1 expression [17, 40] , were significantly suppressed by LBH589 in both the MDA-MB-231 and BT-549 TNBC cell lines, while no change was detected in the MCF-7 samples. To determine if the effects of LBH589 on EMT in TNBC could be overcome by exogenous overexpression of ZEB1 or ZEB2, then MDA-MB-231 cells were transfected with ZEB1, ZEB2, or vector expression plasmids. Following selection, stable expression of ZEB1 and ZEB2 was confirmed by qPCR (Supplemental Fig. 3a , b, respectively) and western blot (Supplemental Fig. 3c ). Furthermore, treatment with LBH589 for 24 h further stimulated the expression of ZEB1 in the MDA-MB-231-ZEB1 cells (Supplemental Fig. 3d ) and ZEB2 in the MDA-MB-231-ZEB2 cells (Supplemental Fig. 3e ). Forced expression of either ZEB1 or ZEB2 modestly, but significantly, reversed the inhibitory effects of LBH589 on MDA-MB-231 cell proliferation (Supplemental Fig. 3f ).
ZEB1/2 expression inhibits LBH589-induced tumor suppressive activity
Most profound, however, were the effects of ZEB overexpression on LBH589-mediated regulation of migration, invasion, and CDH1 gene expression in the MDA-MB-231 cells. The role of ZEBs in LBH589 regulation of cell motility and invasion was tested via migration and invasion assays. MDA-MB-231-vector, ZEB1, or ZEB2 cells were plated in transwell migration (Fig. 3a) or Matrigel Ò coated invasion (Fig. 3b) assays. Cells were treated with vehicle or LBH589 (100 nM) for 6 and 24 h, respectively. The overexpression of either ZEB1 or ZEB2 in MDA-MB-231 cells significantly reversed the ability of LBH589 to inhibit the in vitro migration of MDA-MB-231 cells as well as invasion through Matrigel Ò . ZEB1 or ZEB2 expression also inhibited LBH589-induced CDH1 gene expression to near control levels (Fig. 3c) . These changes were confirmed at the protein level by CDH1 ELISA, which demonstrated a significant reduction of CDH1 expression (Fig. 3d) . An in vivo model was next used to determine if the antitumor effects of LBH589 on TNBC cells previously reported were mediated by regulation of ZEBs. MDA-MB-231-ZEB1 or -ZEB2 cells were injected orthotopically into the mammary fat pad of female SCID/beige mice. Following tumor formation (day 6 post injection), animals were randomized into treatment groups to receive daily injections of either LBH589 (10 mg/kg/day, 5 days/week) or vehicle for 28 days. While LBH589 treatment significantly inhibited tumor growth in the MDA-MB-231-ZEB1 injected mice (Fig. 4a) to similar levels observed in MDA-MB-231 parental cells treated with LBH589, ZEB2 overexpression mitigated the inhibitory effects of LBH589 on MDA-MB-231 tumorigenesis (Fig. 4b) . We previously demonstrated that LBH589 treatment-induced CDH1 protein expression in MDA-MB-231 tumors [11] . However, immunohistochemical staining for CDH1 in tumors from the present study revealed no observable changes in the LBH589-treated ZEB1 or ZEB2 overexpressing tumors compared to their vehicle-treated counterparts (Supplemental Fig. 5 ). Positive staining for CDH1 in the normal luminal ducts within the mammary fat pad tissue adjacent to tumors served as a positive control (bottom panels). These results indicate the effects of ZEB overexpression on CDH1 expression observed in vitro translates to the in vivo setting as well.
Expression of ZEB2 significantly suppresses the effects of LBH589 on EMT gene expression ZEB2 expression appeared to be more affected by LBH589 treatment compared to ZEB1 at the mRNA level, and appeared to have a greater effect on mediating the LBH589-induced effects on migration, invasion, CDH1 gene expression, and most apparently xenograft tumorigenesis. Therefore, MDA-MB-231-ZEB2 cells were examined by qPCR EMT arrays to determine the overall impact of ZEB2 expression on EMT-related gene changes induced by LBH589. As seen in Fig. 5 , ZEB2 overexpression significantly inhibited LBH589-induced expression of CDH1, ERBB3, TSPAN13, and WNT11 (Fig. 5a ) and LBH589-repressed expression of WNT5B, ZEB1, and ZEB2 ( Fig. 5b ; full array data available in Supplemental Table 4 ). These data demonstrate that the effects of LBH589 on TNBC cell biology are regulated at least in part through suppression of ZEB expression, specifically ZEB2.
Discussion
Despite our knowledge of the highly aggressive and metastatic nature of the triple-negative subtype of breast cancer, we have yet to discover truly effective therapies to target this subset of disease. Previously, development of many new therapies was centered on targeting the primary tumor; however, the majority of breast cancer deaths are due to distant metastasis [41] . Once thought to be a late stage event, metastasis has been documented to occur quite early in the progression of breast cancer, particularly in the more aggressive subtypes, including TNBC [42] . Therefore, more focus should be placed on targeting the early pro-metastatic events. The EMT is thought to be one such event, critical to the ability of cancer cells to escape the primary tumor and aid in the development of distant metastases [12] . Identifying agents that can inhibit or reverse this process would be beneficial in the development of anti-metastatic therapeutics.
There have been conflicting findings as to the effects of HDAC inhibitors on cancer metastasis [43] [44] [45] and EMT [46] [47] [48] . Our previous research and the work presented here demonstrate the ability of the pan-DAC inhibitor LBH589 (Panobinostat) to inhibit the expression of classical EMT-associated genes and induce expression of CDH1 in TNBC cell lines but not in luminal (Table 1) or basal A breast cancer cell lines [11] . These findings are supported by recent work by Fortunati et al. [49] that demonstrated LBH589 induction of CDH1 in MDA-MB-231 cells independent of estrogen receptor expression. We also showed LBH589 to be much more potent in its anti-EMT effects than other known HDAC inhibitors, SAHA and TMP269. Additionally, these alterations in EMT gene expression correlate to diminished cell migration and invasion of TNBC in vitro, as well as significant inhibition of TNBC cell metastasis to both brain and lung in a xenograft model. Though LBH589-induced expression of many genes in our qPCR array, we saw significant inhibition of several predominant pro-EMT genes including ZEB1 and ZEB2. Furthermore, forced exogenous expression of ZEB1 or ZEB2 in MDA-MB-231 cells was able to abrogate the inhibitory effects of LBH589 treatment on cell migration, invasion, and CDH1 expression. Known to be significant in direct repression of CDH1 gene expression by binding to the CDH1 promoter, it has recently been shown that the ZEBs also recruit Class I HDAC complexes as co-repressors to inhibit the expression of CDH1 [48, 50, 51] . LBH589 is classified as a pan-DAC inhibitor with potent activity against Class I, II, and IV HDAC enzymes, making it likely that, in addition to inhibition of ZEB expression, LBH589 is able to prevent ZEB-mediated repression of CDH1 by inhibiting the Class I HDACs co-repressors. While ZEB2 expression was able to overcome the antitumor effects of LBH589 in vivo, ZEB1 expression did not have the same effect. Additionally, no change in CDH1 expression was observed in the tumors of either cell line following treatment with LBH589. These results indicate that while LBH589 inhibition of ZEB1 may be involved in Fig. 5 ZEB2 expression inhibits the effects of LBH589 on EMTassociated genes in MDA-MB-231 cells. MDA-MB-231-ZEB2 cells were treated with LBH589 (100 nM) or vehicle (DMSO) for 24 h and analyzed for alterations in EMT-associated genes using the human EMT RT 2 Profiler TM PCR Arrays. Data from ZEB2 overexpressing cell line were compared to previously generated parental data ( Table 1, Supplemental Table 1 ). Graphs represent average fold change of LBH589-treated samples compared to corresponding vehicle-treated samples for a select subset of significantly altered genes (a, b up-and down-regulated genes, respectively). Full data available in Supplemental Table 4 . *p \ 0.05; **p \ 0.01; ***p \ 0.001 compared to LBH589 treated parental data. Arrays were conducted in triplicate the stimulation of CDH1 in vitro, ZEB1 expression alone may not be sufficient to overcome the effects of LBH589 on CDH1 expression in vivo. Rather, the effects of LBH589 on tumorigenesis appear to be regulated more through the repression of ZEB2. Our work here coupled with our previous work support the anti-cancer effects of LBH589 in solid tumors, specifically the triple-negative subtype of breast cancer. Through our studies we have shown that not only does LBH589 work to inhibit TNBC primary tumorigenesis, but LBH589 also inhibits EMT and thus the metastatic potential of TNBC cells. These findings combined with its low nanomolar activity, and favorable clinical responses with limited toxicity in both hematological and solid cancers including breast, make LBH589 an ideal candidate for further development as an anticancer and anti-metastasis therapy in TNBC disease.
